Investors Business Daily
08 Nov 2025, 19:30 UTC · 43w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Merck's new cholesterol pill lowered stubbornly high cholesterol by almost 60%, presenting a competitive threat to injected treatments from Regeneron and Amgen. — An effective oral alternative poses a significant competitive threat to the market share and pricing power of Regeneron and Amgen's injectable cholesterol drugs.
-0.80The cholesterol treatment market is estimated to reach nearly $47 billion by 2033, which Merck's new pill could capture a larger share of. — Merck stands to gain substantial revenue by capturing a slice of a massive and growing market with a highly efficacious oral therapeutic.
+0.60Small caps had their worst day of 2026 as yields and oil prices soared. — Rising yields and oil prices increase borrowing and operating costs, disproportionately hurting smaller companies and dampening risk appetite for small-cap equities.
-0.50Continue reading
5 related stories
Top 1 mover · tap to explore
Tesla raised U.S. Model Y prices for the first time in two years. — Price increases after a two-year hiatus may signal sustained demand or improved pricing power, offering a modest positive signal for Tesla's margins.
+0.30Which stocks this story touches
The company reported a new pill that lowered cholesterol by 60%, potentially capturing a significant share of a $47 billion market.
The company unveiled solid results for an experimental eye disease treatment.
The company faces competition from both Merck in cholesterol treatment and Viridian Therapeutics in eye disease treatment.
The company faces a new potential rival from Merck in the cholesterol treatment market.
The company raised U.S. Model Y prices and established a lower buy point.
[mutual] Merck's new cholesterol pill is described as a potential rival to injections from Amgen.
[mutual] Merck's new cholesterol pill is described as a potential rival to injections from Regeneron.
[mutual] Both companies offer cholesterol injections that Merck is attempting to rival.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
5h ago
